Amanda Blackmon

So proud of @LauraWDillon stepping up to present at a clinical conference today #SOHO23 #SOHO2023 She also today received a ~$1M grant to accelerate the genomics on the MEASURE protocol clinicaltrials.gov/study/NCT05224… #WonderWoman #gettingstuffdone @TheBethesdaLabs @TheACMG @AMPath

Thank you to @mlblack1_b @cityofhope for the write-up of her talk today and the overview of what we are trying to do at @NIH to move precision oncology forward for patients with AML in remission but at continued risk of relapse.

@DanilovLab @jasminezain10 Love this 😎

Lugano with lymphoma wizard Jasmine Zain #ICML17 @jasminezain10

A new guideline from @ASTCT Committee on Practice Guidelines reviews hematopoietic cell transplantation in the management of myelodysplastic syndrome: ow.ly/Cixy50MNmqY #openaccess #MMsm @ELShematology

Nice review on myelofibrosis current&upcoming Rx. Disheartens me however➡️BMT wrapped in 2 paragraphs when it’s the only modality that moves the needle for MF patients & no drugs “in the pipeline” alter natural history #mpnsm #bmtsm ⁦@BloodJournal⁩ ashpublications.org/blood/article/…

Excited for this years ASH meeting - maternal health and hematology sessions we are particularly excited for ashpublications.org/ashnewsdaily/n… @MikkaelSekeres @PishkoMD @aMyeloidPersona @JaneApperley

#ASH22 News Daily Preview is in. Please check out Overview @NatashaSzuber #DEI @JuliPerezBot Maternal health @mlblack1_b @ido amanam Scientific workshops @ManniMD1 @VardellVictoria AI @D_Hermel ASH-a palooza @AutumnJeong @anupumakumar05 @ASH_hematology

It’s a beautiful fall day at the capitol with the @ASH_hematology crew! Ready to #Fight4Hematology and #ConquerSCD! We’re here asking for: ⭐️@NIH funding to $49 billion ⭐️#SCD @CDCgov data collection to $10 million ⭐️#sicklecell Medicaid Demonstration Bill (S.3389 & H.R.6216)

We are excited to share the results of our cost effectiveness analysis of second line axi-cel in DLBCL published in Blood. Despite the high cost of CAR T, we demonstrate that second line axi-cel is cost effective if 5-year EFS is at least 26%. ashpublications.org/blood/article/…

Special thanks to Dr. Amanda Blackmon (City of Hope) for her presentation on "Innovations in Cell Therapy and HSCT" at #Tandem22.

LIFE HISTORY of Investigator-initiated (sponsored) trial (IIT / IST) A🧵 Day 1. An idea. It came to you. Or came to your mentor. You saw something somewhere. Maybe it was @ASH or @ASCO. You connected the dots. Month 1. You discuss it with your group. 1/19

Published now @BloodCancerJNL 📢 Triplets (LIC+VEN+FLT3i) outperforms doublets (LIC+FLT3i) in frontline older/unfit FLT3m #AML. CR/CRi, MFC negativity, and the 2-year OS rates ➡ 93% vs. 70%, 83% vs. 38%, and 70% vs. 22% 👇 nature.com/articles/s4140… @MusaYilmazMD @DaverLeukemia

Can you spot AML w/ inv(3)(q21q26) when you see it? 🕵🏻‍♀️It’s among the most aggressive forms of AML. Diagnostic clues: marked anemia+normal plt count, multilineage dysplasia +/- megakaryocytic hyperplasia and strikingly small megakaryocytes (red arrows) #hemepath 1/ 🧵 #leusm

New diagnosis of AML with normal karyotype with 👇 NGS results. All the driver mutations are present 🤯. What is driving the disease? We need #scDNAseq to decipher the #GameOfClones . @FerrellLabVUMC @rosslevinemd #leusm

📢Out now in @AjHematology via @MDAndersonNews #Leukemia👉 Extended follow up (median 20 mo.) with expanded enrollment (N=45) of FLAG-IDA-VEN in ND-AML | ORR: 98% | CRc: 89% | ⏫ MRD-neg CRc: 93%| 24-month OS 85% in ELN adv. risk w/o TP53 mut. Link👇 bit.ly/39yxbs7

Out now in @TheLancetHaem via @MDAndersonNews Leukemia | Outcomes of venetoclax combined with IC in #AML | VEN+IC👉 improved MRD-negative CR rates, transition to alloHSCT, and EFS compared to IC alone. bit.ly/3OCrBVn #leusm

Great honor to give the E. Donnall Thomas lecture at The 2022 Tandem Meeting

Nice poster on #CKD and outcomes of Flu/Mel allotransplant ⁦@DrMonzrAlMalki⁩ and team! CC: ⁦@ClarkRobinsonMD⁩ ⁦@basmeomeo⁩ docs.google.com/viewer?url=htt…

Exciting to see this prepublished online in @BloodJournal doi.org/10.1182/blood.… We found that the CD19 #CARTcell product type independently impacts outcomes in relapsed or refractory aggressive B-NHL. First CAR-T collaboration between @fredhutch and @OHSUNews 😄

Delighted to share our work optimizing CAR-T cells for acute myeloid leukemia. We're working rapidly on this devastating disease and will be presenting our dual targeting strategy building on this publication in May @ASGCT in Washington DC @Cancer_Cell cell.com/cancer-cell/fu…